Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
21 participants
INTERVENTIONAL
2013-07-31
2023-05-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prostate Adaptive Radiation Therapy
NCT06547398
Salvage Prostatectomy After Radiotherapy
NCT00791115
Tumor TARGET Prostate Cancer
NCT01802242
Radiation Therapy Compared With No Further Treatment Following Surgery in Treating Patients With Prostate Cancer
NCT00002511
Hypofractionated Proton Radiation Therapy for Low and Intermediate Risk Prostate Cancer
NCT01368055
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Post-Operative adaptive radiotherapy
All Patients enrolled in this study will have additional scans (Cone-Beam CT, MRI) daily during their treatment. This extra imaging will help us see any changes that might have occurred during radiation treatment and update the treatment plan to include these changes before patient treatment is continued.
Post-operative Adaptive Radiation Therapy
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Post-operative Adaptive Radiation Therapy
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Clinical stage pT3, pT4, or pT2 with positive margin OR
* Any p-Stage with a persistently elevated post-operative PSA \> 0.05 ng/ml OR
* A delayed rise in PSA post-operatively
Exclusion Criteria
* Prior pelvic radiotherapy
* Previous cytotoxic chemotherapy
* Radiological or pathologic evidence of nodal metastases.
* Planned radiotherapy to pelvic lymph nodes
* Evidence of systemic metastases on imaging.
* Prosthetic hip replacement
* No signed informed consent
18 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Health Network, Toronto
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Charles N Catton, MD
Role: PRINCIPAL_INVESTIGATOR
The Princess Margaret Cancer Foundation
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Health Network, Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
UHN REB 12-5318-C
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.